Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PF-05251749
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Biogen
Deal Size: $710.0 million Upfront Cash: $75.0 million
Deal Type: Acquisition January 13, 2020
Details:
With this purchase, Biogen plans to develop the Phase 1 asset for the treatment of Sundowning in Alzheimer’s disease (AD) and Irregular Sleep Wake Rhythm Disorder in Parkinson’s disease.
Our shared vision is to have a World, free of Pain.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2020
Details:
The Phase I trial aims to demonstrate a favourable safety and tolerability profile and to confirm the pharmacokinetic characteristics of an investigational peripherally restricted Nociceptin/orphanin peptide receptor (NOP) agonist following single and multiple-ascending doses.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): HTL0018318
Therapeutic Area: Neurology Product Name: HTL0018318
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Allergan Plc
Deal Size: $3,290.0 million Upfront Cash: $125.0 million
Deal Type: Terminated January 05, 2021
Details:
AbbVie has notified that it will be returning to Sosei Heptares all assets in development under the program including HTL0018318, all intellectual property licensed by Sosei Heptares to Allergan, and all clinical and preclinical data generated under the partnership.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
